20 rue Jean Mazen Dijon, 21076 Cedex FranceDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

25-27 Avenue du Québec Villebon-sur-Yvette , 91140 FranceDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

19 J.H. Oortweg Leiden, Zuid-Holland, 2333 CH NetherlandsDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

25-27 Avenue du Quebec BP 27627 Villebon-sur-Yvette , 91140 FranceDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

20 rue Jean Mazen BP 27627 Dijon, 21076 Cedex FranceDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

C/O Orcom KVB 60 Broad street, suite 3502 New York, NY, 10004 United StatesDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

18, route du Panorama BP 6 Fontenay-aux-Roses cedex, 92265 FranceDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

11-2901 Rue Rachel Est Montréal, QC, H1W 4A4 CanadaDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

20 rue Jean Mazen B.P. 27627 Dijon, 21076 Cedex FranceDeveloping a new therapeutic involves critical decisions made under pressure. As programs move from validated candidates toward the clinic, the quality, relevance, and interpretation of preclinical data become decisive. At this stage, generating data alone is not enough. What matters is whether the evidence supports confident progression toward clinical development. Oncodesign Services supports biopharma and biotechnology teams navigating this complexity through advanced preclinical pharmacology and translational research services. We specialize in preclinical development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases, with a focus on the translational phase of drug development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects and biodistribution, while model selection and development are tailored to the biological and translational questions driving each study. Experience across preclinical development includes: - 30+ years in preclinical oncology research - 20+ years in preclinical imaging - 10+ years in inflammatory disease research - 10+ years in radiopharmaceutical development Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.